EPISODE · Dec 4, 2020 · 9 MIN
MPR Weekly Dose #60 - The FDA stand by remdesivir; Who should get the vaccine first? Xolair and Hetlioz gain expanded approvals; And a novel neuroblastoma treatment
from MPR Weekly Dose
This week we cover a back and forth between the FDA and the WHO over remdesivir efficacy; Recommendations for who should get a COVID vaccine first; Xolair and Hetlioz have approval expansions; And a novel neuroblastoma treatment gets accelerated approval. Moreover, there's movie trivia!
Embed this episode
Ready to play
MPR Weekly Dose #60 - The FDA stand by remdesivir; Who should get the vaccine first? Xolair and Hetlioz gain expanded approvals; And a novel neuroblastoma treatment
0:00
9:40
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 9 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on December 4, 2020.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!